For US Residents Only | Visit Health Care Professionals Site
Sanofi Pasteur: The vaccines division of Sanofi-Aventis group

A higher dose for patients who
are at a greater risk.1

Image: Find Fluzone Vaccines Near You

Search by Practice or Pharmacy

Search by practice or pharmacy (optional)

Find it now

Ask your health care provider about Fluzone
Intradermal or Fluzone High-Dose vaccine

A higher dose for patients who are at a greater risk.1

As we get older, our immune systems tend to weaken.2 As a result, adults 65 years of age and older are at greater risk for infection and complications from influenza.2-4

Fluzone High-Dose vaccine is the first and only influenza vaccine designed specifically for people 65 years of age and older.3,5 It helps your body make antibodies, substances that can help detect and fight off viruses like influenza.1,6 As a result, when compared to traditional influenza vaccines, Fluzone High-Dose vaccine can provide a stronger immune response in older adults.1,6

There are many different types of flu.6 Fluzone High-Dose vaccine helps protect against the flu virus strains (subtypes A and type B) contained in the vaccine, and not everyone will get the same level of protection.1

Studies have shown that Fluzone High-Dose vaccine is safe for people ages 65 years and older.1 Fluzone High-Dose vaccine is given by injection (shot) in the arm. You may have soreness, mild pain, swelling, fever, headache, fatigue, and muscular pain.1 Fluzone High-Dose vaccine is not appropriate for everybody. Do not receive Fluzone High-Dose vaccine if you or your loved one:1

  • Is under 65 years of age1

  • Has ever had an allergic reaction to a flu vaccine1

  • Is allergic to eggs or egg products1

If you or a loved one is moderately or severely ill at the time of your vaccination, talk to a health care provider about whether or not to reschedule. Your doctor may recommend waiting until the illness has gone away. Typically, people with a mild illness can still get the vaccine.6

Are you ready for a flu vaccine? Find Fluzone High-Dose vaccine using the Fluzone Locator.

Learn About Other Fluzone Vaccines

There’s a Fluzone vaccine for you.

Fluzone High-Dose vaccine is the first and only influenza vaccine designed specifically for people 65 years of age and older.4


Important Safety Information

Indication

Fluzone, Fluzone Intradermal, and Fluzone High-Dose vaccines are inactivated influenza virus vaccines given for active immunization against influenza disease caused by influenza A and B strains contained in the vaccine.

Fluzone vaccine is intended for persons 6 months of age and older.

Fluzone Intradermal vaccine is intended for persons 18 through 64 years of age.

Fluzone High-Dose vaccine is intended for persons 65 years of age and older. Approval of Fluzone High-Dose vaccine is based on superior immune response relative to Fluzone vaccine. Data demonstrating a decrease in influenza disease after vaccination with Fluzone High-Dose vaccine relative to Fluzone vaccine are not available.

Safety Information

Side effects to Fluzone and Fluzone High-Dose vaccines include pain, redness, and swelling at the injection site; muscle aches, fatigue, headache, and fever (irritability, crying, and drowsiness in young children receiving Fluzone vaccine). Redness, firmness, swelling, and itching at the injection site occur more frequently with Fluzone Intradermal vaccine than with Fluzone vaccine. Other side effects may occur. Fluzone, Fluzone Intradermal, and Fluzone High-Dose vaccines should not be administered to anyone with a severe allergic reaction to any vaccine component, including eggs, egg products, or thimerosal (the only Fluzone vaccine product containing thimerosal is the multi-dose vial), or to a previous dose of any influenza vaccine.

Tell the doctor if you/your child has ever experienced Guillain-Barré syndrome (severe muscle weakness) after a previous dose of influenza vaccine. If you notice any other problems or symptoms following vaccination, please contact your health care professional immediately. Vaccination with Fluzone or Fluzone High-Dose vaccine may not protect all individuals.

For more information about Fluzone vaccine, talk to your health care professional and see complete Patient Information
For more information about Fluzone Intradermal vaccine, talk to your health care professional and see complete Patient Information
For more information about Fluzone High-Dose vaccine, talk to your health care professional and see complete Patient Information

References

  1. Fluzone High-Dose vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc.; 2013.
  2. Aspinall R, Del Giudice G, Effros RB, Grubeck-Loebenstein B, Sambhara S. Challenges for vaccination in the elderly. Immun Ageing. 2007;4:9.
  3. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2010;59(RR-8):1-62.
  4. Treanor JJ. Influenza viruses, including avian influenza and swine influenza. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2010:2265-2288.
  5. CDC. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedules for persons aged 0 through 18 years and adults aged 19 years and older—United States, 2013. MMWR 2013;62(Suppl):1-19.
  6. Atkinson W, Wolfe S, Hamborsky J, McIntyre L, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book). 12th ed. Washington, DC: Public Health Foundation; 2011.

PLEASE NOTE

By clicking on this link, you will be leaving this Sanofi Pasteur website and going to another, entirely independent website. Sanofi Pasteur provides this link as a service to its website visitors; however, it takes no responsibility for the information presented on any website but its own.

This link has opened in a new window. To return to your original site, please close this new window.

Click here to go to the page you requested. Click here to close this window and return to the site.